The toxicity of anti-VEGF agents when coupled with standard chemotherapeutics

Cancer Letters

Volumn 357, Issue 1, 2015, Pages 1-7

  Afranie Sakyi, Jennifer A ^a   Klement, Giannoula Lakka ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Anti angiogenic therapy; AVADO; Avastin; Bevacizumab; Breast cancer; Breast cancer treatment; E2100; Metronomic therapy; RIBBON 1; Vascular endothelial growth factor; VEGF

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; PLACEBO; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CARDIOMYOPATHY; CHEMOSENSITIZATION; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INFECTION; INTESTINE DIVERTICULOSIS; MAXIMUM TOLERATED DOSE; METHODOLOGY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND HEALING IMPAIRMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; METRONOMIC DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, METRONOMIC; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84920400299     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.10.028     Document Type: Review

References (42)

1. DeVita V.T., Chu E. A history of cancer chemotherapy. Cancer Res 2008, 68:8643-8653.
2. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2002, 2:795-803.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med 1971, 285:1182-1186.
4. Virchow R. Cellular Pathology: As Based upon Physiological and Pathological Histology 1860, John Churchill, London.
5. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov 2004, 3:391-400.
6. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
7. Hellstrom M., Phng L.K., Hofmann J.J., Wallgard E., Coultas L., Lindblom P., et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007, 445:776-780.
8. Jacobsson K., Gerhardt W., Skude G., Tryding N. [S-GT and alcoholism-soberly considered]. Lakartidningen 1980, 77:987-990.
9. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
10. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun 1989, 161:851-858.
11. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989, 246:1309-1312.
12. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
13. Senger D.R., Perruzzi C.A., Feder J., Dvorak H.F. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986, 46:5629-5632.
14. Clauss M., Gerlach M., Gerlach H., Brett J., Wang F., Familletti P.C., et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med 1990, 172:1535-1545.
15. Broxmeyer H.E., Cooper S., Li Z.H., Lu L., Song H.Y., Kwon B.S., et al. Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor. Int. J. Hematol 1995, 62:203-215.
16. Gressett S.M., Shah S.R. Intricacies of bevacizumab-induced toxicities and their management. Ann. Pharmacother 2009, 43:490-501.
17. Keizer R.J., Huitema A.D.R., Schellens J.H.M., Beijnen J.H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet 2010, 49:493-507.
18. FDA, Proposal to withdraw approval for the breast cancer indication for AVASTIN (bevacizumab), 2011.
19. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med 2007, 357:2666-2676.
20. Miles D.W., Chan A., Dirix L.Y., Cortes J., Pivot X., Tomczak P., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol 2010, 28:3239-3247.
21. Robert N.J., Dieras V., Glaspy J., Brufsky A.M., Bondarenko I., Lipatov O.N., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol 2011, 29:1252-1260.
22. Wen W., Moses M.A., Wiederschain D., Arbiser J.L., Folkman J. The generation of endostatin is mediated by elastase. Cancer Res 1999, 59:6052-6056.
23. Klement G., Huang P., Mayer B., Green S.K., Man S., Bohlen P., et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res 2002, 8:221-232.
24. Scheuerer B., Ernst M., Durrbaum-Landmann I., Fleischer J., Grage-Griebenow E., Brandt E., et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000, 95:1158-1166.
25. Skipper H.E., Schabel F.M., Bell M., Thomson J.R., Johnson S. On the curability of experimental neoplasms. I. Amethopterin and mouse leukemias. Cancer Res 1957, 17:717-726.
26. Skipper H.E., Schabel F.M., Mellett L.B., Montgomery J.A., Wilkoff L.J., Lloyd H.H., et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother. Rep 1970, 54:431-450.
27. Vacca A., Ribatti D., Iurlaro M., Merchionne F., Nico B., Ria R., et al. Docetaxel versus paclitaxel for antiangiogenesis. J. Hematother. Stem Cell Res 2002, 11:103-118.
28. Wang J., Lou P., Lesniewski R., Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003, 14:13-19.
29. Vacca A., Iurlaro M., Ribatti D., Minischetti M., Nico B., Ria R., et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999, 94:4143-4155.
30. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
31. TAXOL®(paclitaxel) INJECTION [package insert], in, Bristol-Myers Squibb Company Princeton, NJ, 2011.
32. Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest 2000, 105:1045-1047.
33. XELODA (capecitabine) [package insert], in, Genentech USA, Inc., South San Franciso, CA, 2011.
34. ABRAXANE (paclitaxel protein-bound particles for injectable suspension) [package insert], in, Abraxis BioScience, LLC, New Jersey, 2013.
35. Doxorubicin Hydrochloride for Injection, USP [package insert], in, Pfizer Labs, New York, 2011.
36. ELLENCE [package insert], in, Pharmacia & Upjohn Co - Division of Pfizer Inc., New York, NY, 2011.
37. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest 2000, 105:R15-R24.
38. Chen C.S., Doloff J.C., Waxman D.J. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia 2014, 16:84-96.
39. Doloff J.C., Waxman D.J. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res 2012, 72:1103-1115.
40. Montagna E., Cancello G., Torrisi R., Rizzo S., Scarano E., Colleoni M. Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report. Ann. Oncol 2010, 21:667-668.
41. Scharovsky O.G., Mainetti L.E., Rozados V.R. Metronomic chemotherapy: changing the paradigm that more is better. Curr. Oncol 2009, 16:7-15.
42. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878-1886.